JP6446065B2 - 抗微生物ペプチドの生成を誘導するためのナイアシンアミド - Google Patents
抗微生物ペプチドの生成を誘導するためのナイアシンアミド Download PDFInfo
- Publication number
- JP6446065B2 JP6446065B2 JP2016567081A JP2016567081A JP6446065B2 JP 6446065 B2 JP6446065 B2 JP 6446065B2 JP 2016567081 A JP2016567081 A JP 2016567081A JP 2016567081 A JP2016567081 A JP 2016567081A JP 6446065 B2 JP6446065 B2 JP 6446065B2
- Authority
- JP
- Japan
- Prior art keywords
- niacinamide
- skin
- composition
- secretion
- coli
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102000044503 Antimicrobial Peptides Human genes 0.000 title claims description 39
- 108700042778 Antimicrobial Peptides Proteins 0.000 title claims description 39
- 230000001939 inductive effect Effects 0.000 title claims description 6
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 title description 50
- 235000005152 nicotinamide Nutrition 0.000 title description 45
- 239000011570 nicotinamide Substances 0.000 title description 45
- 229960003966 nicotinamide Drugs 0.000 title description 45
- 230000015572 biosynthetic process Effects 0.000 title 1
- 210000003491 skin Anatomy 0.000 claims description 41
- 239000000203 mixture Substances 0.000 claims description 38
- 239000003910 polypeptide antibiotic agent Substances 0.000 claims description 34
- 230000028327 secretion Effects 0.000 claims description 17
- 210000002510 keratinocyte Anatomy 0.000 claims description 14
- 210000004761 scalp Anatomy 0.000 claims description 14
- 230000036039 immunity Effects 0.000 claims description 5
- 210000000214 mouth Anatomy 0.000 claims description 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 3
- 229960003512 nicotinic acid Drugs 0.000 claims description 3
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- 150000001408 amides Chemical class 0.000 claims 1
- 244000052616 bacterial pathogen Species 0.000 claims 1
- 235000001968 nicotinic acid Nutrition 0.000 claims 1
- 239000011664 nicotinic acid Substances 0.000 claims 1
- 238000000034 method Methods 0.000 description 20
- 239000006071 cream Substances 0.000 description 19
- 241000588724 Escherichia coli Species 0.000 description 16
- 210000000245 forearm Anatomy 0.000 description 15
- 239000002585 base Substances 0.000 description 13
- 239000000344 soap Substances 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- 102000005871 S100 Calcium Binding Protein A7 Human genes 0.000 description 9
- 108010005256 S100 Calcium Binding Protein A7 Proteins 0.000 description 9
- 238000002965 ELISA Methods 0.000 description 8
- 230000008901 benefit Effects 0.000 description 8
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 description 8
- 235000014113 dietary fatty acids Nutrition 0.000 description 8
- 239000000194 fatty acid Substances 0.000 description 8
- 229930195729 fatty acid Natural products 0.000 description 8
- 150000004665 fatty acids Chemical class 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 239000006210 lotion Substances 0.000 description 8
- 229940030793 psoriasin Drugs 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 7
- 230000014509 gene expression Effects 0.000 description 7
- 244000052769 pathogen Species 0.000 description 7
- 230000007123 defense Effects 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000011282 treatment Methods 0.000 description 6
- 125000003345 AMP group Chemical group 0.000 description 5
- 239000002781 deodorant agent Substances 0.000 description 5
- 229920006227 ethylene-grafted-maleic anhydride Polymers 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 208000001840 Dandruff Diseases 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 239000012228 culture supernatant Substances 0.000 description 4
- 239000012470 diluted sample Substances 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 210000004209 hair Anatomy 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000012737 fresh medium Substances 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000000813 microbial effect Effects 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 239000002453 shampoo Substances 0.000 description 3
- 239000013589 supplement Substances 0.000 description 3
- 229940099259 vaseline Drugs 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 238000002123 RNA extraction Methods 0.000 description 2
- 239000013614 RNA sample Substances 0.000 description 2
- 235000021355 Stearic acid Nutrition 0.000 description 2
- 239000004809 Teflon Substances 0.000 description 2
- 229920006362 Teflon® Polymers 0.000 description 2
- 241000700605 Viruses Species 0.000 description 2
- 229930003537 Vitamin B3 Natural products 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000001166 anti-perspirative effect Effects 0.000 description 2
- 239000003213 antiperspirant Substances 0.000 description 2
- 125000002091 cationic group Chemical group 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000002537 cosmetic Substances 0.000 description 2
- 229940075285 dandruff control Drugs 0.000 description 2
- 239000013024 dilution buffer Substances 0.000 description 2
- 230000001804 emulsifying effect Effects 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- -1 scrub Substances 0.000 description 2
- 238000005201 scrubbing Methods 0.000 description 2
- 239000012064 sodium phosphate buffer Substances 0.000 description 2
- 239000008117 stearic acid Substances 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000000475 sunscreen effect Effects 0.000 description 2
- 239000000516 sunscreening agent Substances 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 235000019160 vitamin B3 Nutrition 0.000 description 2
- 239000011708 vitamin B3 Substances 0.000 description 2
- 101710112984 20 kDa protein Proteins 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 241000218645 Cedrus Species 0.000 description 1
- 208000035484 Cellulite Diseases 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 239000006154 MacConkey agar Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 101710159910 Movement protein Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 206010049752 Peau d'orange Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 206010040829 Skin discolouration Diseases 0.000 description 1
- 101710090398 Viral interleukin-10 homolog Proteins 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 238000010805 cDNA synthesis kit Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000036232 cellulite Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 239000008406 cosmetic ingredient Substances 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 239000007854 depigmenting agent Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 210000003953 foreskin Anatomy 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 239000013003 healing agent Substances 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 230000007803 itching Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000013048 microbiological method Methods 0.000 description 1
- 244000005706 microflora Species 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229940094491 niacinamide 1 mg/ml Drugs 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000003605 opacifier Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 229940114930 potassium stearate Drugs 0.000 description 1
- ANBFRLKBEIFNQU-UHFFFAOYSA-M potassium;octadecanoate Chemical compound [K+].CCCCCCCCCCCCCCCCCC([O-])=O ANBFRLKBEIFNQU-UHFFFAOYSA-M 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000009003 standardized kity Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 239000013026 undiluted sample Substances 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 210000000707 wrist Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
- A61K8/675—Vitamin B3 or vitamin B3 active, e.g. nicotinamide, nicotinic acid, nicotinyl aldehyde
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/005—Antimicrobial preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Birds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Cosmetics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2014/059590 WO2015172801A1 (en) | 2014-05-12 | 2014-05-12 | Niacinamide for inducing generation of antimicrobial peptides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017515829A JP2017515829A (ja) | 2017-06-15 |
| JP6446065B2 true JP6446065B2 (ja) | 2018-12-26 |
Family
ID=50771476
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016567081A Active JP6446065B2 (ja) | 2014-05-12 | 2014-05-12 | 抗微生物ペプチドの生成を誘導するためのナイアシンアミド |
Country Status (8)
| Country | Link |
|---|---|
| JP (1) | JP6446065B2 (es) |
| CN (2) | CN106413680A (es) |
| BR (1) | BR112016024400A2 (es) |
| EA (1) | EA031758B1 (es) |
| MX (1) | MX2016014760A (es) |
| PH (1) | PH12016502047A1 (es) |
| WO (1) | WO2015172801A1 (es) |
| ZA (1) | ZA201607105B (es) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20180030721A (ko) | 2015-08-10 | 2018-03-23 | 마리 케이 인코포레이티드 | 국소 조성물들 |
| CN108135824B (zh) | 2015-10-05 | 2021-09-17 | 联合利华知识产权控股有限公司 | 包含烟酰胺和吡啶2-甲酰胺的组合物 |
| EP3454834B1 (en) * | 2016-05-10 | 2020-09-30 | Unilever N.V. | A topical antimicrobial composition |
| EA201892688A1 (ru) | 2016-05-26 | 2019-04-30 | Юнилевер Н.В. | Противомикробные композиции для местного применения |
| EP3426276B1 (en) | 2017-05-24 | 2024-01-24 | Follea International | Synephrine compositions |
| CN111295190A (zh) * | 2017-10-30 | 2020-06-16 | 荷兰联合利华有限公司 | 烟酰胺用于微生物组平衡的用途 |
| CN111683649A (zh) * | 2017-12-18 | 2020-09-18 | 荷兰联合利华有限公司 | 基于烟酰胺衍生物的局部组合物 |
| CN111491612B (zh) * | 2017-12-18 | 2023-10-20 | 联合利华知识产权控股有限公司 | 局部组合物 |
| WO2019174867A1 (en) | 2018-03-13 | 2019-09-19 | Unilever N.V. | A sanitizer composition |
| WO2024041911A1 (en) * | 2022-08-25 | 2024-02-29 | Unilever Ip Holdings B.V. | A nasal drop composition and device thereof |
| WO2024042554A1 (en) * | 2022-08-25 | 2024-02-29 | Istituto Fondazione Di Oncologia Molecolare Ets | A pharmaceutical composition for treatment of viral infections |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPN892496A0 (en) * | 1996-03-25 | 1996-04-18 | Technical Consultancy Services Pty Limited | Acne treatment |
| US7026308B1 (en) * | 1999-06-25 | 2006-04-11 | The Procter & Gamble Company | Topical anti-microbial compositions |
| MX2007004280A (es) * | 2004-10-15 | 2007-05-16 | Bayer Consumer Care Ag | Composiciones acidas y tamponadas para el cuidado de la piel que comprenden nicotinamida y un agente absorbente. |
| CN101019865A (zh) * | 2007-01-23 | 2007-08-22 | 中国医学科学院皮肤病医院 | 抗炎、保湿、祛斑的复方烟酰胺药用组合物 |
| WO2011133692A1 (en) * | 2010-04-20 | 2011-10-27 | Cedars-Sinai Medical Center | Boosting immune defense by upregulating ccaat/enhancer binding protein epsilon |
| US20130217655A1 (en) * | 2010-10-10 | 2013-08-22 | Dermipsor Ltd. | Compositions for treating psoriasis of the scalp |
| FR2973699B1 (fr) * | 2011-04-05 | 2013-04-26 | Oreal | Nouvel actif apte a induire au stimuler la production de peptides anti microbiens dans le cuir chevelu, utile pour prevenir et/ou traiter les etats pelliculaires du cuir chevelu |
| US8293790B2 (en) * | 2011-10-19 | 2012-10-23 | Dignity Sciences Limited | Pharmaceutical compositions comprising DGLA and benzoyl peroxide and methods of use thereof |
| DE102012002592A1 (de) * | 2012-02-13 | 2013-08-14 | Dr. Kurt Wolff Gmbh & Co. Kg | Verwendung eines Mittels zur Stimulation der Gen-Expression antimikrobieller Peptide (AMP) |
| WO2013186355A1 (en) * | 2012-06-15 | 2013-12-19 | Conaris Research Institute Ag | A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota |
| EP2742942B1 (en) * | 2012-12-14 | 2019-05-22 | Unilever N.V. | Niacinamide for inducing generation of antimicrobial peptides |
-
2014
- 2014-05-12 BR BR112016024400A patent/BR112016024400A2/pt not_active Application Discontinuation
- 2014-05-12 CN CN201480078798.XA patent/CN106413680A/zh active Pending
- 2014-05-12 WO PCT/EP2014/059590 patent/WO2015172801A1/en active Application Filing
- 2014-05-12 JP JP2016567081A patent/JP6446065B2/ja active Active
- 2014-05-12 CN CN202111170332.0A patent/CN113908074A/zh active Pending
- 2014-05-12 EA EA201692284A patent/EA031758B1/ru not_active IP Right Cessation
- 2014-05-12 MX MX2016014760A patent/MX2016014760A/es active IP Right Grant
-
2016
- 2016-10-14 PH PH12016502047A patent/PH12016502047A1/en unknown
- 2016-10-14 ZA ZA2016/07105A patent/ZA201607105B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2017515829A (ja) | 2017-06-15 |
| MX2016014760A (es) | 2017-03-06 |
| WO2015172801A1 (en) | 2015-11-19 |
| BR112016024400A2 (pt) | 2017-08-15 |
| CN106413680A (zh) | 2017-02-15 |
| EA201692284A1 (ru) | 2017-03-31 |
| PH12016502047A1 (en) | 2017-01-09 |
| ZA201607105B (en) | 2018-05-30 |
| EA031758B1 (ru) | 2019-02-28 |
| CN113908074A (zh) | 2022-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6446065B2 (ja) | 抗微生物ペプチドの生成を誘導するためのナイアシンアミド | |
| JP6215206B2 (ja) | 緑茶成分を含有する化粧料組成物 | |
| KR101908679B1 (ko) | 천연 추출물을 함유하는 탈모 방지 및 발모 촉진용 발효 조성물 | |
| EP2742942B1 (en) | Niacinamide for inducing generation of antimicrobial peptides | |
| JP6907196B2 (ja) | ナイアシンアミドとピコリンアミドとを含む組成物 | |
| KR20210011964A (ko) | 피부 병태를 치료하는 방법 | |
| WO2019086327A1 (en) | Use of niacinamide for microbiome balancing | |
| KR101634668B1 (ko) | 겨우살이의 발효된 추출물을 포함하는 항산화 또는 미백용 화장료 조성물 | |
| KR20140133458A (ko) | 부르세라 시마루바 추출물을 포함하는 조성물 | |
| KR102200874B1 (ko) | 키토산을 유효성분으로 포함하는 피부상태 개선용 조성물 및 이의 제조방법 | |
| KR102034436B1 (ko) | 베트남 후피향 추출물을 포함하는 아토피 피부염 치료 및 예방용 조성물 | |
| JP2022536333A (ja) | Ｐａｒ２活性化を阻害する方法、及びそのための組成物 | |
| JP6843537B2 (ja) | 抗皮膚老化剤及びそれを含有する外用化粧料 | |
| KR20160037407A (ko) | 꽃잔디 추출물을 포함하는 항염증제 | |
| AU2021105081A4 (en) | Design and analysis of various formulations of selected herbo cosmeceuticals | |
| KR102337935B1 (ko) | 라크리틴을 포함하는 피부장벽 개선 및 보습 증진용 화장료 조성물 | |
| KR101658616B1 (ko) | 노화 관련 생체단백질의 발현조절이 가능한 황궁채 추출물을 유효성분으로 포함하는 화장료 조성물 | |
| KR101984276B1 (ko) | 베르베린 하이드로클로라이드를 유효성분으로 포함하는 체모성장 저해용 조성물 | |
| JP2023041502A (ja) | 皮膚外用剤 | |
| KR101434446B1 (ko) | 참그물바탕말을 이용한 피부 외용제 조성물 | |
| KR20130102215A (ko) | 트라넥사믹산을 함유하는 아토피성 피부염 치료용 조성물 | |
| JP2011088856A (ja) | ツクシ抽出物を含有する化粧料 | |
| KR20160066254A (ko) | 피크리오노시드 a를 함유하는 모발 또는 두피 상태 개선용 조성물 | |
| JP2014080391A (ja) | 毛髪損傷の予防又は抑制剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170308 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20170308 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20171205 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180305 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20180508 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180905 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20180913 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20181106 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20181130 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6446065 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |